SCHEMBL144068

SCHEMBL144068

[CH2]c1ccc(C(F)(F)F)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 6/20 0.37
KMO O15229 2/20 0.37
DAO P14920 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
IDO1 P14902 3/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
KDR P35968 1/20 0.35
PDE2A O00408 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.33
TDO2 P48775 1/20 0.33
GRM4 Q14833 1/20 0.33
GRM2 Q14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539507 0.83 CYP3A4 (0.34) CYP3A4TSHRMAPK1TDP1PDE2A
SCHEMBL97195 0.82 IDO1 (0.47) NOTUMIDO1HTR3EHTR3BHTR3A
SCHEMBL2046047 0.78 NOTUM (0.37) NOTUMDAOTSHR
SCHEMBL15263626 0.78 STK17B (0.37) IDO1GRM4
SCHEMBL16958432 0.77 CYP3A4 (0.37) CYP3A4TSHRMAPK1TDP1PDE2A
SCHEMBL29403188 0.76 TSHR (0.62) NOTUMKMODAOCYP3A4TSHR
SCHEMBL107751 0.76 TSHR (0.62) NOTUMKMODAOCYP3A4TSHR
SCHEMBL5504987 0.75 PTPN1 (0.46)
SCHEMBL3789260 0.74 PDE2A (0.56) KMODAOTSHRPDE2AMRGPRX4
SCHEMBL364144 0.74 HSD11B1 (0.44) NOTUMKMODAOCYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109678872-B Bisbenzylisoquinoline compound and preparation method and application thereof 山东师范大学 2020-09-29 CN claimed
CN-110577563-B Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs 山东师范大学 2020-09-04 CN claimed
CN-110577563-A Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs 山东师范大学 2019-12-17 CN claimed
EP-2532663-B1 Naphthalenetetracarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2016-03-16 EP claimed
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US claimed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US claimed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US claimed
EP-2532663-A1 Naphthalenecarboxylic acid derivatives and their use as semiconductors BASF SE (DE) 2012-12-12 EP claimed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP claimed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US claimed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP claimed
WO-2008118758-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (GB) 2008-10-02 WO claimed
CN-109678871-B Method for preparing bisbenzylisoquinoline compounds 山东师范大学 2020-09-29 CN disclosed
CN-109678872-B Bisbenzylisoquinoline compound and preparation method and application thereof 山东师范大学 2020-09-29 CN disclosed
CN-110577563-B Fluorine-containing compound, preparation method thereof and application thereof in preparation of antitumor drugs 山东师范大学 2020-09-04 CN disclosed
CN-109776553-B Fuhexine and preparation method and application thereof 山东师范大学 2020-05-29 CN disclosed
US-20070259475-A1 METHOD FOR PRODUCING ORGANIC FIELD-EFFECT TRANSISTORS BASF AKTIENGESELLSCHAFT (DE) 2007-11-08 US disclosed
WO-2007093643-A1 FLUORINATED RYLENETETRACARBOXYLIC ACID DERIVATIVES AND USE THEREOF BASF SE (DE) 2007-08-23 WO disclosed
WO-2007074137-A1 NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS BASF SE (DE) 2007-07-05 WO disclosed
EP-0122488-A1 Bis-(piperazinyl- or homopiperazinyl)-alkanes Boehringer Ingelheim Pharmaceuticals Inc. (US) 1984-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 NOTUM 2496/4885KMO 964/4885DAO 2687/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 NOTUM 2496/4885KMO 964/4885DAO 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.